How one company thinks unraveling cough can provide a new way to treat pain

Source: George Marks/Retrofile/Getty Images

It was a cold night in Boston, and the valets were taking forever, so two neurobiologists got to talking about a fitting topic: pain.

Bruce Bean and Dr. Clifford Woolf, both professors at Harvard Medical School, were vexed by the struggle to come up with viable new painkillers. The therapies of yesteryear dimmed pain but could cause numbness and immobility. Opiates could be addictive. There have been new kinds of painkillers, but they have come with safety and efficacy issues of their own.

“We just started talking about whether there was some novel way that we could selectively target pain-sensing neurons,” Bean said, and the two parted ways with a mutual challenge.

That conversation, between shivering scientists outside a now-defunct French restaurant, set in motion a decade-long quest to build a

You're reading a preview, sign up to read more.

More from STAT

STAT10 min readSociety
Can A New Lyme Disease Vaccine Overcome A History Of Distrust And Failure?
As the threat of Lyme disease grows and fears surrounding it spread faster than the ticks that carry the infection, researchers are developing two vaccine or vaccine-like approaches to prevent this increasingly problematic disease. But don’t expect t
STAT2 min read
Endo Agrees To Pay $10 Million To Settle Landmark Opioid Case Brought By Ohio Counties
As a landmark trial over the opioid crisis grows closer, Endo agreed to a $10 million settlement with two Ohio counties that claimed the drug maker inappropriately marketed its addictive…
STAT3 min readScience
Sarepta Stumbles On FDA Rejection Of A New Drug To Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics was dealt a surprising setback when the FDA rejected its application for a second Duchenne muscular dystrophy drug.